8-甲基-1-萘甲醇 | 10336-29-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-甲基-1-萘甲醇
• 英文名称: 1-hydroxymethyl-8-methylnaphthalene
• 英文别名: (8-methylnaphthalen-1-yl)methanol；8-methyl-1-naphthalenemethanol；8-methylnaphthalenemethanol
• CAS: 10336-29-5
• 化学式: C₁₂H₁₂O
• 分子量: 172.227
• InChiKey: DVSIOMKKABJNIM-UHFFFAOYSA-N

物化性质

• 熔点：
  93-94.5 °C
• 沸点：
  335.4±11.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  8-甲基-1-萘甲醇 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 生成 1-(chloromethyl)-8-methylnaphthalene
  参考文献：
  名称：

  Proximity effects in peri-substituted naphthalenes. I. Some 8-substituted 1-(hydroxymethyl)- and 1-(chloromethyl)naphthalenes

  摘要：

  DOI：

  10.1021/jo01258a047
• 作为产物：
  描述：

  1,8-萘二甲醇 在 萘 、 磷酸 、 lithium 作用下， 以 四氢呋喃 为溶剂， 反应 8.25h， 生成 8-甲基-1-萘甲醇
  参考文献：
  名称：

  苯甲酰化环状醚和胺的还原裂解：合成应用

  摘要：

  在THF中用碱金属还原对称的分子内二芳基甲基醚（3a和8a）和胺（3b和8b）可以生成不对称的经氧或氨基官能化的芳基甲基有机金属。这样的中间体被成功捕获与各种亲电子，允许不对称2,2'-二取代-1,1'-联芳基（一个新的访问5AA - 5BF）和1,8-二取代的萘（10AA - 10BE）。

  DOI：

  10.1016/s0040-4020(00)00783-3

文献信息

• Reductive opening of 1H,3H-benzo[de]isochromene: synthesis of 1,8-difunctionalised naphthalenes
  作者：Francisco Foubelo、Benjamı́n Moreno、Miguel Yus

  DOI：10.1016/j.tet.2004.03.071

  日期：2004.5

  The lithiation of 1H,3H-benzo[de]isochromene (6) with lithium and a catalytic amount of 4,4′-di-tert-butylbiphenyl (DTBB, 5% molar) in THF at −50 °C gives dianionic intermediate 7, which by reaction with different electrophiles H2O, D2O, tBuCHO, PhCHO, Me2CO, (CH3CH2)2CO, [CH3(CH2)4]2CO, (CH2)5CO, (CH2)7CO, (−)-menthone} at the same temperature followed by hydrolysis leads to functionalised alcohols

  1 H，3 H-苯并[ de ]异戊烯（6）与锂和催化量的4,4'-二叔丁基联苯（DTBB，5％摩尔）在-50°C的THF中锂化反应生成双阴离子中间体7，通过与不同的亲电试剂H 2 O，D 2 O，t BuCHO，PhCHO，Me 2 CO，（CH 3 CH 2）2 CO，[CH 3（CH 2）4 ] 2 CO，（CH 2）5一氧化碳，（CH 2）7CO，（-）-薄荷酮}在相同的温度下随后水解导致官能化的醇8。如果在添加羰基化合物作为第一亲电子试剂[ t BuCHO，（CH 2）5 CO，（-）-薄荷酮]后，使生成的二醇二甲酸酯9在0°C下反应，则进行第二次锂化反应，制得中间体如图10所示，其通过与第二亲电试剂[H 2 O，t BuCHO，（CH 2）5 CO，CO 2 ]反应，在水解后产生1，8-双官能化的萘11。在酸性条件下二醇8e的环化–i给出与起始材料6同源的含氧八元杂环。
• New one-pot synthesis of a benzonorcaradiene derivative by reduction of naphthalic anhydride with LiAlH4
  作者：Geerlig W. Wijsman、Lars A. van der Veen、Willem H. de Wolf、Friedrich Bickelhaupt

  DOI：10.1039/a700605e

  日期：——

  Reaction of naphthalic anhydride (naphthalene-1,8-dicarboxylic anhydride) (1) or of 1,8-bis(hydroxymethyl)naphthalene (3) with LiAlH4 in refluxing THF yields the benzonorcaradiene derivatives 2 in yields of up to 50%. It is proposed that in the formation of this (strained) product an anti-hydroalumination reaction is involved, which is facilitated by the assistance of a neighbouring alkoxide function.

  萘酐（萘-1,8-二羧酸酐）（1）或 1,8-双（羟甲基）萘（3）与 LiAlH4 在回流四氢呋喃中反应，生成苯并壬二烯衍生物 2，产率高达 50%。据推测，在形成这种（受约束的）产物的过程中，涉及到一个反氢化镓反应，而邻近的氧化烷官能团则为这一反应提供了便利。
• Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders
  申请人：——

  公开号：US20040142955A1

  公开（公告）日：2004-07-22

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula 1 wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸烷-4-酮衍生物，其一般式为1，其中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。特别地，本发明的化合物可用于治疗焦虑、抑郁、恐慌、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，用于改善认知或记忆能力和情绪稳定。
• Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：Battista Kathleen

  公开号：US20060030577A1

  公开（公告）日：2006-02-09

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下： 其中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心脏心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。
• HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
  申请人：BATTISTA Kathleen

  公开号：US20090124614A1

  公开（公告）日：2009-05-14

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下：其中所有变量均如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。